Mobility is a well-researched priority for individuals with spinal cord injury (SCI). However, most people with SCI experience other, 'secondary' health concerns in addition to mobility impairments. Knowledge of these secondary health outcomes have not been well evaluated in Canadians living with SCI. The primary purpose of this study is to evaluate knowledge levels of secondary health outcomes in individuals with SCI. A secondary objective is to study the knowledge of common post SCI health problems in the general population. This will be done through an online survey. Individuals with an SCI, who take part in the online survey, and who live in the Calgary area, will be invited to take part in a second portion of the study. The purpose of this part of the study is to compare self-reported symptoms of secondary health outcomes with results from physiological assessments of these secondary health outcomes. This will be done during 3 in-person study visits at the University of Calgary. These assessments will involve: 1) Wearing a blood-pressure monitor for 24 hours as you go about your normal routine 2) Lying on a table that adjusts your body from horizontal to vertical, while having your blood pressure monitored 3) Undergoing a DEXA scan

Parkinson's disease or related disorders advance over time. When they do, many of the motor and non motor symptoms also progress. This can include balance troubles, falls and injury. It can also include memory difficulties, hallucinations, pain and aspiration troubles. Our team provides specialized care to provide relief during these advanced stages. It can also give relief from the emotional aspects of the illness. We are a team of specialists who work together. This provides an extra layer of support including help dealing with difficult emotions, daily living challenges, or help at home. There are some expected outcomes from participating in the program, such as improvements in quality of life, mood and possible changes in the perspective of this stage of the disease. Also, some provided tools can help with resources related to community support, financial issues, and long-term needs. If you are interested, you can contact us and we can answer any questions you may have about the research study. Then, if you would like to participate we will perform some questions to determine if you are an eligible candidate.

Researchers at the University of Calgary are interested in determining what barriers and facilitators exist to using and accessing robot-assisted walking devices.

This study explores stress level, difficulty, and tool depth during robot-assisted chest tube insertions. Doctors use chest tubes to drain air and/or blood out of the space around your lungs. This space is surrounded by a membrane, and the doctor's tools can damage your heart and lungs if they go too far past it. Doctors guess tool depth by feeling when the tool has "popped" through this membrane. Sometimes it can be hard to feel the "pop" or to stop right after feeling it, which can lead to accidental organ damage. We've built a robotic system that beeps when tools reach their target depth, and our goal is to measure how much it helps. We test how soon after the "pop" both experts and complete novices can stop tool insertion in simulated routine and emergency scenarios.

The objective of this study is to evaluate the safety and feasability of transauricular vagus nerve stimulation for patients with chronic whiplash associated disorder using a take-home device, a variety of physical measurements, and questionnaires. Approximately 50% of people with chronic whiplash-associated disorders (WAD) continue to report the presence of symptoms 12 months post-injury. These symptoms include high levels of pain and disability as well as psychological symptoms such as anxiety. The nervous system may also be affected, specifically the autonomic nervous system which is responsible for regulating heart rate and blood pressure. An important part of the autonomic system is the vagus nerve, which helps regulate pain and stress responses. Treatment of this nerve via transauricular vagal nerve stimulation (taVNS) has been shown to improve health outcomes in many pain conditions such as chronic low back pain and postural tachycardia syndrome. TaVNS works by sending mild electrical pulses through the ear. This project aims to explore whether or not taVNS can help people with chronic whiplash feel better. Our first goal is to evaluate the safety and feasibility of this type of study. We are interested in learning how many people with chronic WAD participate in the study and how many complete the full treatment, as well as ensuring that the treatment does not cause any serious side effects. Our additional goal is to evaluate the effects of taVNS on neck pain intensity and associated disability, pain sensitivity, heart rate variability, blood pressure, quality of life, anxiety, and depression as measured be questionnaires and physical assessments, as compared to those assigned to the sham treatment.

This study wants to validate a scale called the Brief COPE. This scale measures coping strategies in individuals with Parkinson's Disease (PD) and their care partners. Coping refers to the thoughts and behaviors people use to manage the challenges and stressors they face. Proper coping strategies are crucial for maintaining a good quality of life for people with PD. The Brief COPE is a questionnaire that assesses coping methods for dealing with stressful life events. It has been used in various disorders and populations, but not in PD and care partners. By validating this scale, researchers want to provide a tool to understand and test coping strategies. The study will involve 200 participants, including 100 patients and 100 care partners. The outcomes of this study will contribute to understanding better the coping strategies in PD. To improve the quality of care and support for patients and their care partners.

ABP 692 is an investigational medication that is being developed to be similar to ocrelizumab. The OAK Study will test the pharmacokinetics (how the body absorbs, distributes, and processes the medication), pharmacodynamics (how the medication affects the body), clinical effects, and safety of the investigational ABP 692, compared to the FDA- and European Medicines Agency (EMA)-approved Ocrevus® (ocrelizumab) in people with relapsing-remitting multiple sclerosis. Eligible participants will be assigned randomly (by chance) to receive one of the following treatments: • Group A: 3 infusions of ABP 692. • Group B: 2 infusions of US-ocrelizumab and 1 infusion of ABP 692. • Group C: 3 infusions of EU-ocrelizumab.

In this study we are collecting information about access to genetic testing and genetic care for ALS in Canada. This is a questionnaire study in which we will collect demographic and health information. This will inform how genetic care for ALS is provided across Canada and whether there are opportunities to recommend additional training, support, or resources to certain regions.

We are retrospectively looking a the relationship between mental health, cognition and headaches in the patient with brain injuries that present to the Calgary Brain Injury Program. As well, we are prospectively, looking at exercise behaviours following brain injury in patients that present to the Calgary Brain Injury program and Chronic Pain Centre.

This study is looking for healthy controls to participate in an MRI scan. Healthy controls will be chosen based on age and sex to match a group of patients already recruited for the study. This study requires volunteers to participate in two MRI scans that will be conducted at the Foothills Hospital location. The first scan will be after study enrollment and the second will be a follow-up scan a year later.